By April Larson, MD
Thirteen is shaping up to be a very fortunate number for digital pathologists in 2023. Thanks largely to the efforts of the College of American Pathologists (CAP), the American Medical Association CPT Editorial Board developed 13 new Category III digital pathology digitization procedure codes. The 13 new add-on CPT codes, which have been introduced to record the use of digital pathology, went into effect on January 1.
Prior to 2023, lab reports in the US used the same CPT (current procedural terminology) codes in reporting any diagnostic read—with no distinction made as to whether the diagnosis utilized digital pathology or a glass slide under a microscope. Thus, both procedures earned the same reimbursement rates.
The new CPT codes will help track the additional work and investment of digital pathology into practice and help establish a new standard of care by demonstrating its wider acceptance and usage by the medical community, which in turn is a big step in receiving reimbursement for those services. This will continue to push the medical industry toward the adoption of digital pathology, increasing the availability of remote pathology work for pathologists.
Let’s look at the difference between Category I and the new Category III CPT codes and how they could lead to reimbursement rates for those practices utilizing digital pathology.
The Difference Between CPT Codes
The 13 new Category III codes are designed to be temporary in nature. They’re intended for emerging technology, services, and procedures and allow for the data collection directly associated with carrying them out. The goal is to show that these procedures are becoming more commonly adopted so that pathologists can then work with the AMA to shift these codes to Category I status.
I believe the use of these new CPT codes is a helpful measure that the government can use to determine whether new technology—in this case, digital pathology and the use of AI prognostics— is actually advancing the standard of care.
How do Category III codes differ from Category I codes? According to CAP, the new Category III codes may not meet one or more of the following Category I requirements:
- All devices and drugs necessary for the performance of the procedure or service have received FDA clearance or approval when such is required for the performance of the procedure or service.
- The procedure or service is performed by many physicians or other qualified health care professionals across the United States.
- The procedure or service is performed with a frequency consistent with the intended clinical use (e.g., a service for a common condition should have high volume, whereas a service commonly performed for a rare condition may have low volume).
- The procedure or service is consistent with current medical practice.
- The clinical efficacy of the procedure or service is documented in literature that meets the requirements set forth in the CPT code change application.
Category III codes should be reported only for primary diagnostic use; they should not be reported if the digitization performed is solely for archival or educational purposes, developing a database for training or validation of AI algorithms, or for conference presentations.
The 13 new codes are attached to different services and procedures, but the one thing they all have in common is involving the digitization of glass slides.
The use of these codes is exciting both for dermatologists and dermatopathologists. What we’ve seen at PathologyWatch is that dermatopathologists can benefit from remote digital workflows, and dermatologists have quicker access to both digital slides and reports.
Reclassification to Category I codes, which is the goal, requires meeting both general and specific criteria as determined by the AMA.
Potential Game-Changer for Pathologists
While temporary in nature, the 13 new codes have the potential to be revolutionary for digital pathologists for a variety of reasons. Of primary merit is that the codes are widely expected to achieve Category I status in the near future, opening the door to new financial reimbursements.
Clearly, there are significant upfront expenses associated with digital pathology. The initial technology investment, for example, can seem formidable, with scanners running anywhere from $250,000 to $1 million.
While it is important to note that there are presently no reimbursements directly tied to the new CPT III codes, the change is laying the groundwork by bringing a different dynamic into play.
The utilization of CPT codes helps establish the frequency of usage within the medical community. In order to determine reimbursement, this is often determined by committees of experts who help document the financial investment required to use a new technology.
Much like radiology, the wide adoption of digital pathology will help improve the quality of patient care by promoting sharing of information and images with consulting providers, which improves communication and coordination of care. It also promotes more frequent peer-to-peer and expert consultation with difficult cases and patient education and understanding of their disease.
Reimbursement also provides a financial incentive for clinics and labs to invest further in digital pathology. CAP proposals are being considered for development in the next few years through the AMA CPT process. In the meantime, it is important for dermatologists and dermatopathologists to use the new Category III codes to properly track their digital pathology services.
View a chart with the new CPT codes and detailed explanations of what they entail at cap.org. Then, contact us to learn more about how these new codes, and the adoption of digital pathology, could greatly improve your level of patient care and your practice in general.
— April Larson, MD, is chief medical officer and a cofounder at PathologyWatch.
PathologyWatch, the groundbreaking leader of digital dermatopathology services, has been chosen as one of a select group of 23 startups to participate in the global AWS Healthcare Accelerator: Global Cohort for Workforce.
This AWS Healthcare Accelerator is a four-week technical, business, and mentorship program for startups seeking to use AWS to improve healthcare workforce training, retention, and deployment. This opportunity, which begins in April and runs through the summer, will support PathologyWatch’s efforts to digitally optimize pathology workflows, providing tools that augment dermatopathology resources and interface directly with EHRs. PathologyWatch’s academic-level dermatopathologists can review and provide interpretations for digital slides remotely, supporting clinical decision-making while reducing costs and allowing workplace flexibility.
“We are honored to be one of a few companies chosen for the AWS Healthcare Accelerator program,” says Dan Lambert, CEO and cofounder of PathologyWatch. “Digital pathology is the key to providing quality healthcare solutions to so many underserved areas of the world, including the rural United States. Our mission at PathologyWatch is to leapfrog technology forward in the digital pathology space by connecting individual offices with dermpath experts throughout the world. We believe the AWS Accelerator program can help us in that journey.”
Curriculum of the AWS Healthcare Accelerator will offer opportunities such as hands-on AWS Cloud and technical training, mentorship from healthcare leaders, and exposure to AWS customers and members of the AWS Partner Network. PathologyWatch, which is seeking to advance solutions for addressing urgent challenges facing the healthcare workforce, will also receive AWS computing credits and opportunities to speak with investors and industry experts, including at a Demo Day, where PathologyWatch’s solutions will be showcased.
“Solutions to help clinicians as well as other office and technical staff in healthcare are needed urgently and globally,” says Dr. Rowland Illing, chief medical officer and director of International Public Sector Health at AWS. “We know that advancing cloud- and technology-enabled approaches can alleviate some of the burden, and we’re proud to be convening standout startups and healthcare leaders in this first-ever global Accelerator to do that.”
“We do a significant amount of AI and deep learning research on AWS. They’ve been a great partner,” says Lambert. “The sample volume that we process daily has gone up almost 200% over the past couple of years, and AWS has been able to scale with us. It’s nice having a flexible on-demand hosting solution available immediately.”
Healthcare workforce shortages are at crisis levels, driven by burnout, shrinking budgets, and the aftermath of a worldwide pandemic. A shortfall of 10 million healthcare workers is forecast by 2030. As a result, patients may go untreated or experience delays in care, and healthcare workers need support now more than ever.
In the field of pathology, there is a significant shortage of qualified pathologists, both in the US and worldwide. PathologyWatch is using digital tools to help cover this physician gap, allow pathologists to work remotely, and reduce burnout.
For more information on the AWS Healthcare Accelerator, visit alchemistaccelerator.com/AWS-Healthcare-Accelerator.
Dr. George brings years of dermatopathology experience to the firm, with a special focus on melanoma.
Salt Lake City, November 4, 2021—PathologyWatch, a full-service digital pathology service, is pleased to welcome Dr. Eva Vertes George, MD, to its clinical team. A highly qualified and respected dermatopathologist, Dr. George’s expertise in melanoma, autoimmune conditions and inflammatory skin conditions aligns with PathologyWatch’s goals to support the most comprehensive and best-quality patient care while reducing healthcare costs.
“We are impressed with the enthusiasm and depth of expertise that Dr. George brings to the people of Florida and all over the United States,” says Dan Lambert, cofounder and chief executive officer of PathologyWatch.
Dr. George completed her residency in anatomic and clinical pathology at the University of Florida. Her fellowship was in dermatopathology at the University of Florida, and she is US-board certified in anatomic and clinical pathology and dermatopathology.
Although she enjoys all aspects of clinical pathology, her focus is melanoma. “I love it all, but I would say the part that grabs me is melanoma. There’s still so much that we don’t know about them. As we continue understanding the different variants, it’s about making sure we get the correct diagnosis so that patients receive the best care possible.”
As a strong supporter of digital pathology, Dr. George was drawn to PathologyWatch in part because of its commitment to opening up access to qualified patient care to the international community. “The idea that a biopsy can be done anywhere in the world, digitized, and then read by a pathologist from a different place in the world is very exciting. The possibilities are endless with that kind of instant accessibility,” said Dr. George.
“One of the most valuable parts of digital pathology is that it is going to enhance the accuracy of the diagnosis in a timely manner. It enables the transfer of information more readily and then extends that service to rural areas,” said Dr. George. “I truly believe digital pathology is the future.”
For more information, please email [email protected] or visit us at pathologywatch.com.
PathologyWatch is the groundbreaking leader of digital dermatopathology services. Through these services, dermatology clinics, hospitals and laboratories can improve operational efficiency by speeding up workflow and enhancing patient outcomes by utilizing the PathologyWatch expert professional team and laboratory services. This can facilitate best-in-class reads and, in some cases, enable additional revenue to the practice by in-housing pathology. With an intuitive and easy-to-implement digital pathology solution that includes access to top-tier dermatopathologists and a streamlined clinical workflow that interfaces directly into the EMR, PathologyWatch brilliantly combines state-of-the-art technology and clinical decision-making to deliver unprecedented patient care.